Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06167434
Other study ID # FC-2022-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2023
Est. completion date December 2024

Study information

Verified date January 2024
Source Future Cardia, Inc
Contact Jaeson Bang
Phone +1 727 470 3466
Email jaeb@futurecardia.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a first-in-human, prospective, multi-center, pre-market single-arm clinical trial to evaluate the Future Cardia™ ICM.


Description:

The objective of this first-in-human, prospective, multi-center, pre-market single-arm clinical investigation is to evaluate the safety and performance of the Future Cardia™ ICM by assessing the insertion procedure, sensing and detection performance and data monitoring transmission success, and device- or procedure-related complication rates over a 6-month follow-up period.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Adult patients (=18 years old and <75 years old) 2. Paroxysmal AF, defined as AF that terminates spontaneously or with intervention within 7 days of onset (ESC 2020 guidelines). In order to be included, patients must present one of the following conditions: 1. paroxysmal AF patients that are candidates for AF ablation; 2. patients hospitalized for symptomatic AF, who failed to convert in the emergency room (ER): 3. outpatients who require treatment with anti-arrhythmic drugs (AAD) (mostly propafenone or flecainide; more rarely sotalol or amiodaron are given for PAF). 3. Patient is willing and able to provide written informed consent. 4. Patient is willing and able to comply with the protocol, including follow-up visits and data transmissions. Exclusion Criteria: 1. Patient who is scheduled to have MRI or is likely to require MR screening. The Future Cardia implant is not compatible with MRI. 2. Currently indicated for or implanted with a cardiovascular implantable electronic device (CIED) (e.g., ICM or ILR, pacemaker, ICD, CRT-D or CRT-P device) or hemodynamic monitoring system. 3. Compromised immune system or at high risk of developing an infection. 4. Active systemic infection or history of any infection within the last 30 days. 5. Subjects who are female must: 1. have a negative pregnancy test by ß-hCG blood test. 2. not breastfeeding 3. either be surgically sterile, postmenopausal (cessation of menses for at least 1 year), or if they have childbearing potential, agree to use a medically accepted, highly effective method of contraception during the entire duration of the study. 6. Subject is currently enrolled in another investigational study. 7. Any condition or abnormality (including clinical laboratory, physical examination, or vital sign abnormalities), current or past, that, in the opinion of the Investigator, would compromise the efficacy evaluation, safety of the patient, or would interfere with or complicate study procedures or assessments. 8. Any concomitant condition which, in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse, emotional/psychological diagnosis). 9. Obesity, Class 2 (BMI = 35-40) or Class 3 (BMI = 40). 10. Subject is unwilling or unable to comply with the study procedures. 11. Subject is legally incapacitated and unable to provide written informed consent. Exclusion criteria for the study procedure: 12. Patient with abnormal thoracic anatomy or scar tissue at the implant site that may adversely impact the insertion procedure. 13. For patients currently taking warfarin at the time of insertion, most recent INR value (within 7 days) is less than 3.5 for an acceptable risk of bleeding.

Study Design


Intervention

Device:
Future Cardia™ Insertable Cardiac Monitoring (ICM) System
The Future Cardia™ ICM procedure will be performed as a stand-alone procedure for subcutaneous insertion.

Locations

Country Name City State
Croatia University Hospital of Split Split

Sponsors (2)

Lead Sponsor Collaborator
Future Cardia, Inc Meditrial Europe Ltd.

Country where clinical trial is conducted

Croatia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Characterization of Insertion Procedure - Implantation: Insertion Success Insertion Success. (Yes/No) Day 0
Primary Characterization of Insertion Procedure - Implantation: Incision Size Incision Size in millimeters (mm). Day 0
Primary Characterization of Insertion Procedure - Implantation: Device Orientation Device Orientation: Location between the suprasternal notch and the left nipple, (position A); or left parasternal region (position B) or left sub-mammary position can be used (position C). Day 0
Primary Characterization of Insertion Procedure - Implantation: Duration of Insertion Procedure. Duration of Insertion Procedure in minutes (min). Day 0
Primary Characterization of Explant Procedure - Device removal: Removal Success Removal Success (Yes/No) up to 6 months
Primary Characterization of Explant Procedure - Device removal: Incision Size Incision Size in millimeters (mm) Up to 6 months
Primary Characterization of Explant Procedure - Device removal: Duration of explant procedure Duration of explant procedure in minutes (min). Up to 6 months
Primary Device and Procedural Safety over a period of 180 days Number of Serious Adverse Events (SAE) related to the Device or insertion procedure.
Number of Participants with Device-related or Procedure-related Serious Adverse Event that require additional invasive intervention (including need to for device removal, device replacement, surgical repositioning of the device, or another surgery related to the device or primary insertion procedure).
6 months
Primary Success of Wireless Transmissions over a period of 180 days Assess the percentage of successful wireless transmissions from the system throughout the study duration (transmission successful, the transmission failed or transmission re-try). 6 months
Secondary Evaluation of the sensing quality of Future Cardia™ ICM, through assessment of the ECG signal by two independent electrophysiologists. ECG signal Assessment. 6 months
Secondary Comparison of the Future Cardia™ ECG tracing and detection of arrhythmias with 7-day ECG recorder tracings or 24-hr Holter recording (optional, when available). Comparison of the Future Cardia™ ECG tracing and detection of arrhythmias with 7-day ECG recorder tracings or 24-hr Holter recording. 6 months
Secondary Usability: survey of the implanting physicians regarding the ease of implantation and use of the system for monitoring during follow-up. Usability Survey 6 months
Secondary Number of Serious Adverse Events (SAE) related to the Device or study procedure in patients who elect to continue monitoring using the ICM device after the 6-month study follow-up. Long-term safety in Post study follow-up (> 6 months up to 2 years). 2 Years
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A